remibrutinib
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pressure score
30
Momentum score
5
Why This Matters
Pfizer is a direct competitive threat because it has a development-stage program in Neurology · Multiple Sclerosis (remibrutinib) and could narrow Novartis's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Share risk is emerging — primarily strategic positioning rather than immediate revenue displacement.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer's remibrutinib directly references the same indication focus (Neurology · Multiple Sclerosis) as this signal.
Source: Pfizer
View source documentRelated Signal
Novartis Evaluates Remibrutinib for Secondary Progressive Multiple Sclerosis
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #3 of 3
Bristol Myers Squibb
1 competitive finding
Top program: remibrutinib
- Pressure
- 61
- Momentum
- 20
- Threat
- direct competitor
- Stage
- Phase III
61Bristol Myers SquibbMediumremibrutinib·Phase III
Roche
3 competitive findings
Top program: remibrutinib
- Pressure
- 59
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
59RocheMediumremibrutinib·Stage unknown
Pfizer
1 competitive finding
Top program: remibrutinib
- Pressure
- 30
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
30PfizerLowremibrutinib·Stage unknown